Company intelligence / Profile preview

Covagen AG

Zurich, Zurich canton, Switzerlandjnj.com ↗

Ownership: Private
Employees: ~23
Development stage: Phase 1

Overview

Covagen developed a proprietary platform for generating bispecific and multispecific protein therapeutics called FynomAbs by fusing human Fynomer binding proteins to antibodies. Their lead candidate COVA322 entered Phase 1b clinical trials for psoriasis and targeted both TNF-alpha and IL‑17A. Other programs included preclinical assets in oncology and autoimmune disease. The company was acquired by Cilag GmbH International (Janssen/Johnson & Johnson) in August 2014; development of some programs has since been discontinued or integrated into the parent pipeline.

Therapeutic areas: OncologyImmunology
Modalities: Bispecific antibodies (FynomAbs)fusion proteinsprotein therapeutics
Industry: Biotech

Drug pipeline

1 asset

COVA 322

Phase 1

Indications: Psoriasis, Rheumatoid arthritis

Partnerships

Investors included Novartis Venture Fund, Edmond de Rothschild Investment Partners; acquired by Cilag/Janssen/J&J which became the key partner/owner post-acquisition

Beyond the preview

Go deeper on Covagen AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Covagen AG.

Explore the full profile